The HemOnc Pulse Live
Advertisement
Mazyar Shadman, MD; Meghan Thompson, MD; Alan Skarbnik, MD continue their discussion on MRD in CLL during HOP Live 2024.
Among the major dilemmas persisting in CAR-T therapy use is how to balance malignancy risks.
Dr. Shammo gives her impressions of how growing incorporation of MDS molecular data is changing disease management.
This episode explores questions in CLL with Mazyar Shadman, MD; Meghan Thompson, MD; Alan Skarbnik, MD during HOP Live 2024.
The expert panel discusses current issues in the use of ESAs within MDS management.
Dr. Pemmaraju discusses three major unanswered questions for myeloproliferative neoplasm researchers.
Advertisement
In a roundtable discussion, an expert panel discussed how approval of luspatercept has affected frontline MDS treatment.
Amer Zeidan, MBBS, discusses the unanswered questions in research related to myelodysplastic syndromes.
The expert panel describes how having two separate classification systems for MDS affects their clinical practices.
The expert panel discusses how to explain to patients the range of MDS severities and approach lower-risk disease.
The expert panel discusses molecular testing's current place in MDS evaluation and treatment decisions.
In a roundtable discussion, an expert panel describes recent trends in the classification and prognosis of MDS in the clinic.
Dr. Usmani offers his take on treating smoldering myeloma and using MRD as a prognostic factor.
At the 'HemOnc Pulse' Live meeting in Chicago, an expert panel explores unanswered questions in T-cell lymphoma management.
The panel considered whether it’s time for new response criteria in myelofibrosis such as anemia improvement.
Michael Bishop MD; Aaron Goodman, MD; and Rafael Fonseca, MD, discuss bispecifics in hematologic malignancies.
An expert panel convened at the "HemOnc Pulse" Live meeting in Chicago explores unanswered questions in DLBCL management.
The panel discussed ALL treatment, associated toxicities, and the possibility of a chemotherapy-free approach.
The panel mainly discussed frontline tyrosine kinase inhibitors for the treatment of chronic phase CML.
The panel discussed treatment options for Hodgkin lymphoma, maintenance therapy following autologous transplant, and more.
Advertisement
Advertisement
Editorial Board
Sagar Lonial, MD, FACPEditor-in-Chief | Chief Medical Officer of Winship Cancer Institute at Emory University School of Medicine
Guillermo Garcia-Manero, MDAssociate Editor | Chief, Section of Myelodysplastic Syndromes, The University of Texas MD Anderson Cancer Center
Elias Jabbour, MDExecutive Editor | DB Lane Cancer Research Fund Distinguished Professor in Leukemia Research, MD Anderson Cancer Center
Kami Maddocks, MDAssociate Editor | Professor of Clinical Internal Medicine in the Division of Hematology at The Ohio State University
Thomas Martin, MDAssociate Editor | Clinical Research Director, UCSF Helen Diller Family Comprehensive Cancer Center
Jerald Radich, MDAssociate Editor | Professor in the Clinical Research Division and Kurt Enslein Endowed Chair at Fred Hutch
Laurie Sehn, MD, MPHAssociate Editor | Clinical Professor of Medical Oncology, British Columbia Cancer Centre for Lymphoid Cancer
630 Madison Ave.
Manalapan, NJ 07726
© 2024 Mashup Media, LLC, a Formedics Property. All Rights Reserved.